Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 2/20 | 0.63 |
| ▸ | LMNA | P02545 | 1/20 | 0.63 |
| ▸ | TSHR | P16473 | 1/20 | 0.63 |
| ▸ | MAPT | P10636 | 2/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.51 |
| ▸ | ATM | Q13315 | 1/20 | 0.50 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | P2RX7 | Q99572 | 3/20 | 0.46 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | HTR2C | P28335 | 2/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29741392 | 1.00 | HPGD (0.63) | HPGDLMNATSHRMAPTSMN1; SMN2 | |
| SCHEMBL29741382 | 0.96 | LMNA (0.61) | HPGDLMNATSHRMAPTSMN1; SMN2 | |
| SCHEMBL7294542 | 0.86 | MAPT (0.66) | HPGDLMNATSHRMAPTSMN1; SMN2 | |
| SCHEMBL24196349 | 0.84 | MAPT (0.56) | HPGDLMNATSHRMAPTSMN1; SMN2 | |
| SCHEMBL20180887 | 0.84 | SMN1; SMN2 (0.56) | HPGDLMNATSHRMAPTSMN1; SMN2 | |
| SCHEMBL12444391 | 0.82 | MAPT (0.58) | HPGDLMNATSHRMAPTSMN1; SMN2 | |
| SCHEMBL22537420 | 0.82 | MAPT (0.55) | HPGDLMNATSHRMAPTSMN1; SMN2 | |
| SCHEMBL11115287 | 0.82 | MAPT (0.58) | HPGDLMNATSHRMAPTSMN1; SMN2 | |
| SCHEMBL7806296 | 0.82 | MAPT (0.54) | HPGDLMNATSHRMAPTSMN1; SMN2 | |
| SCHEMBL24416848 | 0.82 | LMNA (0.48) | HPGDLMNATSHRMAPTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11377443-B2 | Pharmaceutical compounds | CellCentric Limited (GB) | 2022-07-05 | — | — | US | disclosed |
| EP-1592426-B1 | 2-CYANOPYRROLOPYRIMIDINES AND PHARMACEUTICAL USES THEREOF | NOVARTIS AG (CH) | 2007-12-19 | — | — | EP | disclosed |
| WO-2004069256-A1 | 2-CYANOPYRROLOPYRIMIDINES AND PHARMACEUTICAL USES THEREOF | NOVARTIS AG (CH) | 2004-08-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11377443-B2 | Pharmaceutical compounds | EP300, HDAC1, HDAC11 | HPGD 1818/4885LMNA 2948/4885TSHR 3664/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.